Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications, including Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Breyanzi, Opdualag, Camzyos, Zeposia, Abecma, Sotyktu, Krazati, Cobenfy, Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel, Abraxane, and Augtyro. The company sells to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. It has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen for kidney cancer. Formerly known as Bristol-Myers Company, it was founded in 1887 and is headquartered in Princeton, New Jersey.
Bristol Myers Sotyktu Shows Two-Year PsA Efficacy in POETYK Study
Bristol Myers Squibb announced positive two-year results from the late-stage POETYK PsA-2 study of Sotyktu, or deucravacitinib, including its open-label extension. Among patients entering the extension, clinical responses improved from week 16 through week 52 and were sustained through week 104, with robust results across ACR20/50/70 and Minimal Disease Activity in both continuous Sotyktu patients and those who switched from placebo at week 16. The safety profile remained consistent through week 104 with no new safety signals; adverse events occurred in 86.6% of 604 patients exposed to Sotyktu, while serious adverse events and discontinuations due to adverse events were reported in 12.6% and 7.6% of patients, respectively. Sotyktu, an oral selective tyrosine kinase 2 inhibitor approved in the United States and numerous other countries for moderate-to-severe plaque psoriasis and active psoriatic arthritis, generated $156 million in first-half 2026 revenues, up 24% year over year. Data from the POETYK SLE-1 and SLE-2 studies in systemic lupus erythematosus are expected later in 2026, while Amgen's Otezla and Takeda's investigational zasocitinib, whose new drug application the FDA recently accepted for plaque psoriasis, remain competitive threats.
Pfizer's Dividend Streak Stalls at $0.43 as Peers Keep Raising
Pfizer's decade-long streak of annual dividend increases has stalled, with its quarterly payout holding at $0.43 through the September 1, 2026 payment after the January 2026 ex-dividend date matched the prior four quarters instead of rising. The 6.20% yield remains covered by reaffirmed 2026 adjusted diluted EPS guidance of $2.80 to $3.00 against a run-rate $1.72 annual payout, and Q1 2026 adjusted EPS of $0.75 beat consensus for a fifth consecutive quarter above estimates. Cash outflow is real, with $2.4 billion in dividends paid in Q1 alone and $9.8 billion for full-year 2025, while Pfizer completed no buybacks in 2025 and anticipates none in 2026 despite $3.3 billion of unused authorization. On the August 4, 2026 call, incoming interim CFO Cecile Guegan said Pfizer would keep maintaining and over the long term growing the dividend, and Chairman and CEO Albert Bourla said the dividend will be maintained and eventually start growing again after the loss-of-exclusivity period. Peers have not frozen their payouts: Merck raised its quarterly from $0.81 to $0.85 starting with the December 2025 ex-date, and Bristol-Myers Squibb nudged its payout from $0.62 to $0.63 with the January 2026 ex-date. The pressure behind the pause is visible in the mix, with Comirnaty down 59% and Paxlovid down 62% in Q1 2026 and roughly $1.5 billion in additional generic and biosimilar headwind guided for the year, partly offset by launched and acquired products growing 22% operationally and Vyndamax exclusivity now running to June 2031.
Supernus Pharmaceuticals reported second-quarter revenues of $211.3 million, up 27.7% year on year and exceeding analysts' expectations by 2.8%, as the broader group of 9 branded pharmaceuticals stocks tracked reported a strong quarter with revenues beating consensus estimates by 6.6% as a group. The company said full-year operating income guidance exceeded analysts' expectations and full-year revenue guidance slightly topped them, prompting President and CEO Jack Khattar to cite the continued strength and sustained momentum of its growth products and continued execution on its commercial strategy. Despite the beat, Supernus shares are down 5.9% since reporting and currently trade at $41.99. Among peers, Bristol-Myers Squibb reported revenues of $12.97 billion, up 5.7% year on year and 12.9% above expectations, while Corcept Therapeutics posted revenues of $256.1 million, up 31.7% and 21.6% above estimates, the biggest beat and highest full-year guidance raise of the group. Zoetis delivered the weakest performance, with revenues of $2.47 billion, flat year on year and 1.5% below expectations, alongside a significant miss of full-year EPS guidance estimates.
Bristol-Myers Squibb reported positive two-year Sotyktu results in psoriatic arthritis and affirmed a quarterly dividend of US$0.63 per share for November payment. The clinical and income news arrives as the company's share price has climbed 16.37% over the past 90 days and 17.55% year to date, with a 1-year total shareholder return of 44.42%. Bristol-Myers Squibb last closed at $62.84, while the most followed narrative pegs fair value at $66.21, a small valuation gap the market has not fully closed. The company's pipeline and life-cycle management for major brands, plus strategic partnerships with BioNTech, Philochem and Bain, are seen as offsetting upcoming patent expiries, though heavy dependence on drugs facing those expiries and increasing drug pricing pressure remain key risks.
Redwire Expands Microgravity Platform With 11 ISS Payload Facilities
Redwire Corporation is expanding its microgravity capabilities beyond traditional space missions into scientific research, biotechnology and advanced manufacturing. The company has built a growing microgravity platform with 11 active payload facilities on the International Space Station as of Dec. 31, 2025, and has launched 42 Pharmaceutical In-space Laboratory – Bio-crystal Optimization eXperiment, or PIL-BOX, payloads. During 2025, Redwire entered a licensing agreement with ExesaLibero Pharma under which it is eligible to receive royalties from commercial sales of resulting pharmaceutical products. Bristol Myers Squibb and Eli Lilly have both partnered with Redwire on PIL-BOX missions to study pharmaceutical molecules and crystal growth in microgravity. The Zacks Consensus Estimate for 2026 and 2027 earnings per share suggests year-over-year growth of 57.32% and 40%, respectively, while Redwire trades at a forward 12-month price-to-sales of 4.92X versus an industry average of 2.29X.
Arm CEO Says AI Could Cure Cancer, But Chip Shortage Holds It Back
Arm Holdings CEO Rene Haas said artificial intelligence could help find a cure for cancer within our lifetime, but warned that chip shortages are limiting the expansion of AI infrastructure. In an interview with the BBC, Haas said AI could eventually solve complex problems in cancer research and accelerate drug development, though modelling cells and DNA markers remains too complex today. The computing requirements for AI-driven drug discovery are already substantial, with Generate Biomedicines co-founder Gevorg Grigoryan noting that large-scale model training needs access to many GPUs, plus proprietary biological data. Bristol Myers Squibb has deployed a new NVIDIA AI computing system to support research across cancer and other therapeutic areas. Haas described the industry as in an "absolutely supply-constrained environment," saying more chip factories are needed to support growing data centers, but manufacturing capacity cannot be added overnight. He also said Arm's power-efficient technology is used in about half of AI data centers worldwide, and demand for Arm's AGI chip, developed with Meta Platforms, has exceeded $2 billion since its launch.
Bristol Myers Squibb announced positive topline results from the registrational Phase 2 QUINTESSENTIAL trial of arlocabtagene autoleucel, a potential first-in-class GPRC5D-directed CAR T cell therapy, in patients with quadruple-class exposed relapsed and refractory multiple myeloma. The trial met its primary endpoint of overall response rate and key secondary endpoint of complete response rate in this heavily pretreated population who had received prior BCMA-targeted therapy. QUINTESSENTIAL is the first pivotal trial to evaluate a therapy in quadruple-class exposed patients following prior BCMA-targeted therapies, and arlo-cel is designed as a single infusion. The safety profile was consistent with other CAR T cell therapies. Full results will be presented at an upcoming medical meeting.
Cytokinetics Presents New Aficamten Data, Plans sNDA for nHCM
Cytokinetics announced additional results from its ACACIA-HCM and MAPLE-HCM studies at the European Society of Cardiology Congress 2026, showing that aficamten improves cardiac structure and diastolic function in non-obstructive HCM and outperforms metoprolol across pre-trial treatment groups in obstructive HCM. The company plans to submit a supplemental new drug application for aficamten in nHCM in the fourth quarter of 2026, potentially expanding its market beyond the approved oHCM indication under the brand name Myqorzo. The FDA has already accepted Cytokinetics' sNDA for MAPLE-HCM, with a target action date of November 14, 2026. Myqorzo faces competition from Bristol Myers Squibb's Camzyos and Edgewise Therapeutics' EDG-7500, which is entering phase III in late 2026. Cytokinetics shares have gained 12.4% year to date, and the Zacks Consensus Estimate for 2026 loss per share has narrowed to $6 from $6.26 over the past 60 days.
Novartis Halts CAR-T Trials After Three Patient Deaths
Novartis has paused eight clinical trials of an experimental CAR-T therapy targeting autoimmune and neurological disorders after three patients died from a severe immune response, the Wall Street Journal reported. The Swiss pharmaceutical company temporarily halted the studies in late August and is conducting a comprehensive review of the safety events, which it describes as a known risk in CAR-T therapies. Novartis is working with independent safety boards overseeing each paused study and sharing information with regulators. Bristol-Myers Squibb has also paused similar trials of its CAR-T treatment in autoimmune disorders as a precautionary measure.
Bristol Myers Squibb Presents Five-Year Camzyos Data at ESC Congress
Bristol Myers Squibb presented results from the EXPLORER-LTE cohort of the MAVA-LTE study at the European Society of Cardiology Congress 2026, showing that Camzyos (mavacamten) provides sustained efficacy and safety for up to five years in patients with symptomatic obstructive hypertrophic cardiomyopathy. The single-arm, open-label extension of the Phase 3 EXPLORER-HCM study included 231 patients, with 97.4% achieving a Valsalva left ventricular outflow tract gradient of 30 mm Hg or less, 69.6% improving by at least one New York Heart Association class, and 59.2% becoming asymptomatic at 252 weeks. Mean resting and Valsalva LVOT gradients decreased by 38.7 mm Hg and 55.6 mm Hg, respectively, while left ventricular ejection fraction decreased by 10.2% but remained within normal range. Additional real-world data from the COLLIGO-HCM study and a German registry reinforced the drug's effectiveness across diverse populations, and a Swedish healthcare resource utilization study highlighted the disease burden of HCM. No new safety signals emerged, and the findings support Camzyos as the most-studied cardiac myosin inhibitor, with over 25,000 patients treated in the U.S. alone.
J&J's China Pill Approval Challenges Its Own Injection Franchise
Johnson & Johnson won Chinese approval for its once-daily oral psoriasis treatment Icotyde, a pill that could compete with its own injectable drug Tremfya. The approval targets a market of more than 8.4 million people in China with moderate-to-severe plaque psoriasis, though local pricing, launch timing, and sales guidance remain undisclosed. Icotyde blocks the IL-23 receptor and was supported by a Phase 3 program of roughly 2,500 patients, which also underpinned its earlier U.S. approval. The convenience of a pill may attract patients who avoid injections, but converting Tremfya users would merely shift revenue within J&J, so real growth depends on untreated patients or taking share from rivals like AbbVie and Bristol Myers Squibb. At $266.59, the stock trades 38.32% above its GF Value estimate of $192.73, leaving little room for a soft launch.
U.S. pharmaceutical giant Johnson & Johnson (J&J) announced on the 27th that Chinese drug regulators have approved its oral psoriasis treatment Icotide. China has more than 8.4 million psoriasis patients, and in this market, J&J's Tremfya, Bristol-Myers Squibb's Sotyktu, and AbbVie's Skyrizi are among the competitors. Analysts point out that Icotide, as a once-daily oral medication, could become a blockbuster and take market share from injectables. Icotide is approved for the treatment of moderate to severe plaque psoriasis, and Chinese companies such as InnoCare Pharma and Takeda are also developing oral treatments.
FDA Approves Bristol-Myers Squibb's Zenbexus for Multiple Myeloma
The U.S. FDA has approved Bristol-Myers Squibb's oral blood-cancer drug iberdomide, sold as Zenbexus, for patients with relapsed or refractory multiple myeloma, given with Johnson & Johnson's Darzalex and dexamethasone. The approval adds a potential growth driver to BMY's oncology portfolio, supported by late-stage data showing improved minimal residual disease rates versus standard therapy. Zenbexus has a list price of $29,500 for a 28-day cycle, and about 36,000 new U.S. cases are expected this year. However, the drug received accelerated approval, requiring confirmatory trials, and carries a boxed warning for embryo-fetal toxicity, distributed through a restricted program. Competition in multiple myeloma remains intense, so Zenbexus may build into a growth driver over time rather than an immediate game changer.
Bristol-Myers Squibb to Spend $2.3 Billion on Houston Plant
Bristol-Myers Squibb announced on August 10 that it will invest about $2.3 billion in a new manufacturing plant in Houston, part of a larger $40 billion U.S. investment pledge. The roughly 600,000-square-foot campus will produce small-molecule medicines, biologics, and antibody-drug conjugates, and is expected to create close to 500 skilled jobs and about 2,000 construction jobs between 2027 and 2030. Texas is providing $4.89 million in state funding for the project. The move comes as drugmakers including Eli Lilly, Johnson & Johnson, and Pfizer expand U.S. manufacturing amid tariff pressure from the Trump administration. Separately, British regulators cleared Eli Lilly's weight-loss pill Foundayo for weight management and type 2 diabetes, making the UK the first country in Europe to approve the drug.
Bristol Myers Raises 2026 Outlook on Eliquis Strength
Bristol Myers Squibb raised its full-year 2026 revenue guidance to $49-$50 billion, up from $46-$47.5 billion, after Eliquis sales grew 19% to $8.6 billion in the first half. The company now expects Eliquis revenue growth of 20-25% for the year, versus a prior 10-15% forecast, and legacy portfolio revenues to decline 4-6% instead of 12-16%. Eliquis, co-commercialized with Pfizer, posted 22% growth in the second quarter, helping offset generic erosion for Revlimid, Pomalyst, Sprycel and Abraxane. Management still expects Eliquis sales to decline by $1.5-$2 billion in 2027.
Bristol Myers Squibb Partners With Chai Discovery on AI Antibody Discovery
Bristol Myers Squibb announced a new collaboration with Chai Discovery to advance AI-driven therapeutic antibody discovery. The agreement focuses on using artificial intelligence and machine learning to support the identification of novel therapeutic antibody candidates. The move reflects Bristol Myers Squibb's effort to integrate advanced computational tools into its drug discovery work. Investors should watch for pipeline updates where the company attributes new antibody programs or faster candidate selection to this AI system.
Corcept Leads Branded Pharma Q2 With 21.6% Revenue Beat
Corcept Therapeutics reported second-quarter revenues of $256.1 million, up 31.7% year on year and beating analysts' expectations by 21.6%, making it the standout performer among eight branded pharmaceutical stocks tracked. The company also beat EPS estimates and raised full-year revenue guidance above expectations, with its stock up 28.1% since reporting to trade at $119.05. Bristol-Myers Squibb posted revenues of $12.97 billion, up 5.7% and 12.9% above estimates, while Eli Lilly delivered the fastest revenue growth at 47.7% to $22.97 billion, beating by 11.4%. Zoetis was the weakest, with flat revenues of $2.47 billion missing estimates by 1.5% and lowering full-year guidance. Supernus Pharmaceuticals reported $211.3 million in revenue, up 27.7% and 2.8% above estimates.
Seaport Therapeutics IPO Draws Big Pharma Attention
Seaport Therapeutics has emerged as a potential acquisition target for major pharmaceutical companies following its May 2026 IPO. The company's Glyph prodrug platform has generated 24 candidates, with lead asset GlyphAllo entering Phase 2b for major depressive disorder and topline results expected in the first half of 2027. Bristol Myers Squibb, which previously paid $14 billion for Karuna Therapeutics co-founded by Seaport CEO Daphne Zohar, is ranked as the top potential acquirer. Johnson & Johnson, AbbVie, and Sanofi are also named as plausible buyers. Seaport completed an upsized $260 million IPO and holds $427.26 million in cash, guiding to a runway into 2029.
Healthcare ETFs Hit One-Year Highs on Earnings and M&A
Healthcare ETFs are hitting one-year highs as the sector benefits from improving earnings visibility, attractive relative valuations, and a rotation out of overcrowded AI and tech trades into defensive growth. State Street Health Care Select Sector SPDR ETF XLV has surged 6.6% over the past month compared with 3.4% gains for State Street SPDR S&P 500 ETF Trust SPY. S&P 500 healthcare companies are expected to deliver double-digit earnings growth from Q4 2026 through 2027, and the sector is expected to log a 21.2% increase in earnings on 2.2% higher revenues, according to Zacks Sector and Market Earnings Trends issued on Aug. 12, 2026. M&A value in the sector has touched nearly $284 billion this year, approaching 2025's total of $306 billion, and hedge fund bets in favor of healthcare stocks recently neared a five-year high, per a Goldman Sachs note. The FDA has accelerated its approval process, with the annual number of new drug approvals in 2025 reaching its highest level since 2020.
Hematogenix assay underpins FDA accelerated approval of Bristol Myers Squibb's ZENBEXUS
Hematogenix announced that its proprietary Next Generation Flow Cytometry assay for multiple myeloma minimal residual disease served as the analytical method for the pivotal efficacy endpoint supporting the FDA's accelerated approval of Bristol Myers Squibb's ZENBEXUS (iberdomide), the first CELMoD therapy approved for multiple myeloma. The FDA-approved prescribing information states that MRD-negative complete response was assessed using a Hematogenix Next Generation Flow Cytometry assay at a threshold of 10⁻⁵. In the Phase 3 EXCALIBER-RRMM trial, patients treated with ZENBEXUS in combination with daratumumab and hyaluronidase-fihj and dexamethasone achieved an MRD-negative complete response rate of 41%, compared with 21% for patients treated with daratumumab, bortezomib, and dexamethasone, a statistically significant improvement with p<0.0001. Hematogenix President and CEO Dr. Hytham Al-Masri said being named directly in the FDA label for the first approved therapy in a novel drug class validates the precision and scientific rigor of the company's laboratory platform. Hematogenix operates CAP-accredited and CLIA certified laboratories in the United States, United Kingdom, Malaysia, and China.
Aktis Oncology, a clinical-stage radiopharmaceutical company, is seen as a potential acquisition target for Novartis, Eli Lilly, and Bristol Myers Squibb due to its alpha-emitting cancer platform and upcoming trial data. Aktis retains full worldwide rights to its miniprotein radioconjugate platform, with $517.3 million in cash and preliminary data from its lead candidate AKY-1189 expected in the first quarter of 2027. Novartis, whose Pluvicto grew 43% in Q2 2026, and Eli Lilly, already a $60 million upfront partner, rank as the top two strategic acquirers. Analysts target $34.42 for AKTS while the 24/7 Wall St. base case reaches $42.16, but a failed readout would erase the takeout premium entirely.
China Surpasses US in Drug Development, Supply Chain
China has pulled ahead of the United States in clinical drug development and supply chain, two of six domains measured in a June Cure Innovation Index survey, even as Big Pharma signs billion-dollar deals for Chinese-developed medicines. Dr. Nathan Goodyear of Williams Cancer Institute told Benzinga that roughly a third of new drugs Big Pharma licensed in came from Chinese labs, up from almost none a decade ago. Bristol Myers Squibb signed a $15.2 billion collaboration with Jiangsu Hengrui Pharmaceuticals in May covering 13 early-stage programs, while Merck reached a $2 billion licensing agreement in March 2025 for HRS-5346, a cardiovascular drug developed entirely in China. The U.S. Department of Health and Human Services launched Operation TrailBlazer in late June, and Congress introduced the Biotech Investment National Security Act to screen outbound biotech investment, building on the Biosecure Act signed into law in December 2025. The survey of 117 senior U.S. industry and academic leaders found 76% say the U.S. leads but China is closing fast, 85% say the U.S. lead lasts 10 years or less, and 72% agree China is improving faster than the U.S.
AstraZeneca and Bristol Myers Squibb Discuss Potential Mega-Merger
AstraZeneca and Bristol Myers Squibb have reportedly held talks about a potential merger, a deal that would create a pharmaceutical giant but faces significant hurdles. Analysts note AstraZeneca already has one of the strongest organic growth profiles in pharma, on track to hit $80 billion in annual sales by 2030, and a merger would force it to absorb Bristol Myers Squibb's looming patent cliff on key drugs like Eliquis. The deal could also trigger antitrust scrutiny given both companies' dominance in cancer care, and a straight cash and debt buyout is essentially impossible with Bristol Myers having deal capacity of around $32 billion and AstraZeneca around $37 billion. The discussion comes amid a perception that the current administration is more merger-friendly, potentially encouraging other big pharma companies to pursue defensive mega-mergers.
Bristol Myers Squibb is facing a revived $6.7 billion lawsuit after a federal appeals court reinstated claims tied to its Celgene acquisition. Plaintiffs allege the company deliberately delayed FDA approval of certain drugs to avoid paying contingent value rights owed to former Celgene shareholders. The appeals court decision brings renewed legal and financial uncertainty related to how the Celgene transaction was structured. The case does not directly affect the scientific strength of the pipeline or recent approvals such as ZENBEXUS, but it could influence how investors think about potential cash calls, management bandwidth and the risk premium applied to a business that is also contending with patent cliffs and pricing pressure.
Vinod Khosla Says AI Creates Hyperabundance of New Drugs but Testing Lags
Venture capitalist Vinod Khosla said artificial intelligence is rapidly expanding drug discovery, but traditional testing methods have failed to keep pace with the technology's progress. In a post on X, Khosla said AI has produced what he described as a 21st-century hyperabundance of potential new drugs and biological hypotheses, while drug testing still relies heavily on conventional animal studies. He argued that the industry needs a more human-relevant approach to evaluating potential treatments, pointing to Vivodyne, a biotechnology company developing technology to test drugs using living human tissues at scale. Khosla also said he was excited to continue working with Vivodyne as the company develops its Virtual Human data center, which he said could eventually help researchers predict how patients will respond to treatments. The article also noted that Anthropic launched Claude Science, an AI workbench for scientific research, Takeda reported its AI-developed psoriasis drug zasocitinib significantly outperformed Bristol-Myers Squibb's Sotyktu in a Phase 3 trial, and Nvidia and Eli Lilly announced a $1 billion AI co-innovation lab.
Bristol Myers Squibb Wins FDA Approval for ZENBEXUS
Bristol Myers Squibb received FDA accelerated approval for ZENBEXUS in a multiple myeloma combination regimen, marking the first approved CELMoD therapy in this disease setting. The approval comes as the stock trades at $64.65, with a 30-day return of 13.52%, a year-to-date return of 20.93%, and a one-year total shareholder return of 41.71%. Analysts following the most popular narrative value the stock at $62.96, about 3% below the current price, citing declining revenue but rising margins and a higher future P/E. The company's current P/E of 14.2x is below the US Pharmaceuticals industry average of 16.6x.
FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS for Multiple Myeloma
The U.S. Food and Drug Administration has granted accelerated approval to Bristol Myers Squibb's ZENBEXUS, the first CELMoD therapy, in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. Approval was based on Phase 3 EXCALIBER-RRMM results showing the ZDd regimen doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone, at 41% versus 21%. ZENBEXUS carries Boxed Warnings for embryo-fetal toxicity and venous and arterial thromboembolism, and is available only through a restricted REMS program. Bristol Myers Squibb also noted that a New Drug Application for mezigdomide, another investigational CELMoD, is under FDA review with a target date of May 13, 2027.
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
Atrium Therapeutics reported second quarter 2026 financial results and announced FDA clearance of its IND application for ATR 1072, enabling the launch of the Corventis Phase 1/2 trial in PRKAG2 syndrome. The company also earned a second milestone payment of $15 million under its global cardiovascular collaboration with Bristol Myers Squibb, which will be recorded in the third quarter. Collaboration revenue was $3.0 million for the quarter, while R&D expenses were $15.3 million and G&A expenses were $10.3 million. As of June 30, 2026, Atrium had $263.9 million in cash, cash equivalents and short-term investments, which the company believes is sufficient to fund operations through mid-2028. The Corventis trial is expected to enroll its first participant by the end of 2026, with initial proof-of-concept data anticipated in the second half of 2027.
Bristol Myers Growth Portfolio Sales Rise 13% in First Half
Bristol Myers Squibb's growth portfolio sales rose 13% in the first half of 2026, lifting its share of total revenues to 56% from 51.8% a year earlier. The portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyku, Krazati and Cobenfy. Opdivo Qvantig is now generating annualized revenues of more than $1 billion. Legacy products including Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane still account for 44% of revenues and face erosion from loss of exclusivity. Bristol Myers shares have gained 17.9% year to date, and the Zacks Consensus Estimate for 2026 EPS has risen to $6.81 from $6.32 over the past 60 days.
AstraZeneca and Bristol-Myers Squibb call off merger talks
The Financial Times reports that merger talks between British pharmaceutical giant AstraZeneca and US peer Bristol-Myers Squibb have been terminated. The deal would have created one of the world's largest drugmakers with a market capitalisation of around 400 billion dollars. The two sides had been nearing an agreement on a plan for AstraZeneca to buy Bristol-Myers Squibb shares at a premium, aiming for an announcement in mid-August. However, the day after the talks were reported on 3 August, AstraZeneca's board decided to call them off.
AstraZeneca shares plunge 9% on report of merger talks with Bristol-Myers Squibb
AstraZeneca shares suffered their biggest one-day drop since 2020, closing down as much as 9%, after reports emerged that the company held merger talks with U.S. rival Bristol-Myers Squibb. A combined entity would be worth close to $400 billion, making it the fourth-largest drugmaker globally by market value, though neither firm confirmed the discussions and people familiar with the matter told Reuters a deal may never materialize. Investors and analysts reacted with skepticism, with Jefferies analysts saying they were "a bit perplexed" given AstraZeneca's strong growth trajectory under CEO Pascal Soriot, who recently reiterated the company does not need M&A to reach its $80 billion annual revenue target by 2030. Union Investment's Markus Manns called the idea strategically and financially unsound, while ATG Healthcare's Lukas Leu described it as growth-dilutive in the near term. Bristol-Myers Squibb shares initially rose as much as 6% on the news, reflecting a view that the company needs a deal more urgently as its top products Eliquis and Opdivo face looming patent expirations, though BMO's Evan Seigerman warned that antitrust concerns over overlapping cancer drugs could reduce the odds of a successful merger.
Bristol Myers Squibb to build $2.3 billion Houston campus
Bristol Myers Squibb announced it will build a $2.3 billion drug manufacturing campus in Houston, Texas, as part of its broader $40 billion five-year U.S. investment commitment. The roughly 600,000-square-foot facility at Generation Park will produce small molecules, biologics, and antibody-drug conjugates, with a design allowing its production footprint to adapt to the company's pipeline. The campus is expected to employ nearly 500 people and support about 2,000 construction workers through 2030. Texas Governor Greg Abbott said the project is eligible for a $4.89 million Texas Enterprise Fund grant and meets criteria for state incentives under the Jobs, Energy, Technology and Innovation program. Bristol Myers raised its full-year revenue guidance to approximately $49 billion to $50 billion, driven by drugs including Eliquis, Camzyos, and Reblozyl.
Eli Lilly, Novo Nordisk, and Pfizer lead healthcare news after quarterly results
Eli Lilly, Novo Nordisk, and Pfizer were among the notable healthcare companies reporting quarterly results this week. Eli Lilly posted better-than-expected second-quarter results driven by its GLP-1 drugs, with revenue of $23 billion beating consensus by $2.3 billion, and raised its full-year revenue guidance to a range of $85.0 billion to $87.0 billion, though the midpoint fell short of the $85.4 billion consensus. Novo Nordisk lifted its full-year outlook for the second time this year on GLP-1 strength, now expecting sales and operating profit to decline by no more than 6% at constant exchange rates, but its U.S.-listed shares fell as much as 6%. Pfizer topped second-quarter expectations with adjusted earnings per share of $0.77 and revenue of $15.03 billion, and raised its full-year revenue guidance by $500 million at the midpoint to $60.5 billion to $62.5 billion. Merck also reported better-than-expected second-quarter results and raised its full-year revenue guidance to $66.3 billion to $67.3 billion, but lowered its adjusted earnings per share forecast to $2.66 to $2.76, below the $2.76 consensus, due to charges from its Terns acquisition. Bristol-Myers Squibb fell after a Reuters report said there are no discussions with AstraZeneca about a potential deal, contradicting earlier reports of preliminary merger talks. Integer Holdings agreed to be acquired by KKR in an all-cash deal valued at approximately $5.7 billion, with stockholders receiving $127.00 per share. The S&P 500 Health Care Index Sector gained 1.92% during the week, with Charles River Laboratories and Veeva Systems among the top gainers, while DaVita and Insulet were among the top losers.
FDA Approves Replimune's Skin Cancer Drug on Third Attempt
U.S. biopharmaceutical company Replimune Group announced it has received accelerated approval from the U.S. Food and Drug Administration for its difficult-to-treat skin cancer therapy RP1, brand name Tudriqev. The drug is intended for use in combination with Bristol Myers Squibb's cancer immunotherapy Opdivo for patients with advanced melanoma who have not responded to prior treatments. The two previous applications were rejected due to issues with trial design and insufficient evidence of efficacy. RP1 works by injecting a genetically modified herpes virus directly into tumors. The average price for one course of treatment is set at 450,000 dollars, with shipments expected to begin in about 60 days. A confirmatory late-stage clinical trial for full approval is underway, with data expected in 2030.
Alzheimer's Disease Market Projected to Reach USD 4 Billion in 2025 with 22.7% CAGR Through 2036
The Alzheimer's disease market across the seven major markets was valued at approximately USD 4 billion in 2025 and is projected to expand at a CAGR of 22.7% through 2036, according to DelveInsight. The growth is driven by increasing disease prevalence, broader adoption of disease-modifying therapies, advancements in biomarker-based diagnosis, and a robust late-stage pipeline. Key emerging therapies include Masupirdine from Suven Life Sciences, Roche's Trontinemab, Annovis Bio's Buntanetap, AB Science's Masitinib, Eli Lilly's Remternetug, Axsome Therapeutics' AUVELITY, Biovie's Bezisterim, ALZHEON's Valiltramiprosate, TauRx Therapeutics' Hydromethylthionine mesylate, Bristol Myers Squibb's COBENFY, AriBio's AR1001, Acadia Pharmaceuticals' Remlifanserin, and Cerecin's Tricaprilin. The report highlights six late-stage candidates poised to enter the market, including Masupirdine, Trontinemab, AXS-05, COBENFY, Remternetug, and Buntanetap, each with distinct mechanisms of action and anticipated clinical milestones.
Schrödinger Expands AI Co-Scientist Deal With Bristol Myers Squibb After Posting Q2 Profit
Schrödinger, Inc. reported second-quarter 2026 revenue of US$58.89 million and a shift to a US$5.98 million net profit, while expanding its collaboration with Bristol Myers Squibb to deploy its agentic AI co-scientist, Bunsen, across the partner's research organization. The expanded Bunsen agreement connects Schrödinger's new AI tool to a large existing customer, reinforcing the catalyst around deeper usage within top accounts and broader AI module adoption. Alongside the earnings turnaround, the company also highlighted an ESOP shelf registration that ties employee incentives to the success of Bunsen and related AI offerings. The investment narrative projects US$349.6 million in revenue and US$23.4 million in earnings by 2029, requiring 11.1% yearly revenue growth and a US$126.9 million earnings increase from a current loss of US$103.5 million. The biggest risk remains whether higher-value software adoption can offset ongoing margin pressures and volatile collaboration income.
Companies defy macro uncertainty and raise guidance
A growing number of companies are raising their profit outlooks despite macroeconomic uncertainty. More S&P 500 firms are lifting guidance than cutting it, and Wall Street analysts have raised third-quarter earnings estimates for the index for the second consecutive quarter. Argus research analyst Christine Dooley views consistent guidance raises as a catalyst for market-beating returns. Among the companies that have raised guidance in the second quarter so far are Cheesecake Factory, Ford, General Motors, Hasbro, Starbucks, Coca-Cola, Charles Schwab, PayPal, US Bancorp, ASML, Seagate Technology, Supermicro Computer, Bristol Myers Squibb, Johnson & Johnson, UnitedHealth Group, 3M, Lockheed Martin, Northrop Grumman, United Airlines, and United Parcel Service.
Schrödinger and Bristol Myers Squibb Strike Deal to Deploy AI Co-Scientist Bunsen for Drug Discovery
Schrödinger has entered a strategic collaboration and software agreement with Bristol Myers Squibb to deploy Bunsen, its agentic AI co-scientist, within BMS's research organization. The deal significantly expands BMS's use of Schrödinger's computational platform, enabling scientists to explore more possibilities, prioritize molecules with greater confidence, and accelerate discovery decisions. The collaboration includes developing novel functionality within Bunsen alongside Schrödinger's computational technologies for large-scale chemical exploration and its AI-driven synthesis planning platform RetroSynth. Bunsen is optimized to execute Schrödinger's validated, physics-based computational platform by planning and running complex molecular discovery workflows and interpreting results. BMS, a long-standing customer, will adopt Bunsen at scale, empowering a broader group of scientists to embrace a predict-first computational approach.
Global stocks surge on easing US-Iran tensions, oil drop fuels risk appetite
US stocks closed at a record high, with the Dow jumping 693.38 points after US-Iran tensions eased, sending WTI crude down over 5% and US Treasury yields lower. Communication services led the rally, surging 4.3%, driven by Meta Platforms and Alphabet, while Amazon climbed 4.6%, pushing its market value past 3 trillion dollars for the first time. In Europe, the STOXX 600 index closed up 0.45%, with aerospace and defense stocks jumping 2.7%. AstraZeneca tumbled 9% on reports of a merger deal worth over 400 billion dollars with Bristol Myers Squibb, dragging the healthcare sector down 1.7%. Asian markets mostly rose this morning, led by South Korea's KOSPI, which gained 1.5% after President Trump called off plans to strike Iran, easing energy supply and inflation concerns. The Thai stock market has a chance to recover, with BANPU resuming trading as a new entity after completing its merger with BPP, aiming to diversify away from coal and expand into data centers and energy storage systems.
AstraZeneca in advanced merger talks with Bristol Myers Squibb for $400 billion deal
AstraZeneca is reported to be in advanced merger talks with Bristol Myers Squibb, a deal that could create a combined pharmaceutical company valued at about US$400 billion. The potential transaction would rank among the largest in the sector and significantly affect competitive positions in oncology, though regulators are expected to review any agreement closely due to overlapping product portfolios. A combination would bring together large pipelines and marketed therapies in cancer, immunology, cardiovascular, and rare diseases, reshaping how AstraZeneca competes with rivals like Pfizer, Merck, and Roche. Investors are cautioned that the discussions remain in a preliminary phase, and any deal would likely require divestments to address antitrust concerns, particularly in the U.S. market where Bristol Myers is firmly established.
USA